<?xml version="1.0" encoding="UTF-8"?>
<p>No significant difference was observed in the frequency of symptoms between the two groups. There was no difference in acute pain intensity between the two groups (VAS 8.78 in the bDMARD group; 9.04 in the control group; 
 <italic>p</italic>=0.615) or in the chronic phase (VAS 5.23 in the bDMARD group; 5.08 in the control group; 
 <italic>p</italic>=0.85). No cases of complications or death were reported in either group.
</p>
